Desmoid tumors located in the abdomen or associated with adenomatous polyposis: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)

• Published in: Digestive and liver disease 2022-06, Vol.54 (6), p.737-746
• Main Authors: Benech, Nicolas, Bonvalot, Sylvie, Dufresne, Armelle, Gangi, Afshin, Le Péchoux, Cécile, Lopez-Trabada-Ataz, Daniel, Meurgey, Alexandra, Nicolas, Nayla, Orbach, Daniel, Penel, Nicolas, Salas, Sébastien, Saurin, Jean-Christophe, Walter, Thomas, Lecomte, Thierry, Bouché, Olivier
• Format: Article
• Language: English
• Subjects: Abdomen; Cancer; Combined Modality Therapy; Desmoid tumors; Desmoid-type fibromatosis; Familial adenomatous polyposis; Fibromatosis, Aggressive; Fibromatosis, Aggressive - diagnosis; Fibromatosis, Aggressive - therapy; Follow-Up Studies; French clinical practice guidelines; Humans; Life Sciences; Mesenchymal tumors; Prospective Studies; Soft tissue sarcoma
• ISSN: 1590-8658; 1878-3562
• DOI: 10.1016/j.dld.2022.03.004

Desmoid tumor (DT) of the abdomen is a challenging and rare disease. The level of evidence available to document their treatment is relatively low, however, recent publications of prospective studies have allowed to precise their management. This document is a summary of the French intergroup guidelines realized by all French medical and surgical societies involved in the management of DT located in the abdomen or associated with adenomatous polyposis. Recommendations are graded in four categories (A, B, C and D), according to the level of evidence found in the literature until January 2021. When the diagnosis of DT is suspected a percutaneous biopsy should be performed when possible. A molecular analysis looking for pathogenic mutations of the CTNNB1 and APC genes should be systematically performed. When a somatic pathogenic variant of the APC gene is present, an intestinal polyposis should be searched. Due to a high rate of spontaneous regression, non-complicated DT should first benefit from an active surveillance with MRI within 2 months after diagnosis to assess the dynamic of tumor growth. The treatment decision must be discussed in an expert center, favoring the less toxic treatments which can include broad spectrum tyrosine kinase inhibitor or conventional chemotherapy (methotrexate-vinblastine). Surgery, outside the context of emergency, should only be considered for favorable location in an expert center. French guidelines for DT management were elaborated to help offering the best personalized therapeutic strategy in daily clinical practice as the DT therapeutic landscape is complexifying. Each individual case must be discussed within a multidisciplinary expert team.